Introduction

bluebird bio, Inc. (NASDAQ: BLUE) recently announced its participation in the Center for Medicare and Medicaid Innovation’s (CMMI) Cell and Gene Therapy (CGT) Access Model. This initiative is designed to enhance patient access to advanced gene therapies through outcomes-based agreements that link payments to treatment effectiveness. This significant step reflects bluebird bio’s commitment to equitable access and value-based care for patients insured through Medicaid.

Details of the Initiative

The CGT Access Model, introduced by CMMI in response to President Biden’s Executive Order 14087 on lowering prescription drug costs, is a voluntary program involving states and manufacturers. It aims to:

• Improve Medicaid beneficiaries’ access to innovative treatments.
• Enhance health outcomes.
• Reduce overall healthcare costs.

bluebird bio will offer outcomes-based agreements for its one-time gene therapy, LYFGENIA™ (lovotibeglogene autotemcel), approved for patients aged 12 and older with sickle cell disease and a history of vaso-occlusive events. These agreements align payments with the therapy’s real-world effectiveness.

bluebird bio’s Commitment

Tom Klima, Chief Commercial & Operating Officer at bluebird bio, emphasized the company’s dedication to equitable access, stating:

“Ensuring timely, equitable access to gene therapy for people living with sickle cell disease insured through Medicaid has been a cornerstone of our commercial approach since approval, and we are pleased to build on this commitment by offering an outcomes-based agreement to state Medicaid agencies through the Cell and Gene Therapy Access Model.”

Benefits of the CGT Access Model

By participating in this model, bluebird bio aims to address key barriers to access for gene therapies, particularly the high upfront costs that can limit availability for Medicaid patients. The outcomes-based agreements ensure:

• Cost alignment with patient benefits.
• Increased accessibility for Medicaid beneficiaries.
• Support for healthcare systems in adopting value-based care models.

Conclusion

bluebird bio’s participation in the CMMI CGT Access Model represents a pivotal move toward making transformative gene therapies more accessible to those who need them most. This collaboration highlights the importance of innovative payment models in addressing healthcare inequities and promoting better outcomes for patients covered by Medicaid.